U.S. Markets closed

Vermillion, Inc. (VRML)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.32-0.01 (-0.75%)
At close: 4:00PM EDT
People also watch
ROSGPSDVBASIAPRIVCYT
Full screen
Previous Close1.33
Open1.35
Bid0.00 x 0
Ask0.00 x 0
Day's Range1.30 - 1.35
52 Week Range0.76 - 2.85
Volume22,538
Avg. Volume40,775
Market Cap74.14M
Beta1.82
PE Ratio (TTM)-6.14
EPS (TTM)-0.22
Earnings DateMay 18, 2017 - May 19, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.75
Trade prices are not sourced from all markets
  • Capital Cube2 hours ago

    ETFs with exposure to Vermillion, Inc. : September 19, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Vermillion, Inc. Here are 5 ETFs with the largest exposure to VRML-US. Comparing the performance and risk of Vermillion, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Vermillion, Inc. :VRML-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
    Capital Cubeyesterday

    Vermillion, Inc. :VRML-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017

    Categories: Yahoo FinanceGet free summary analysis Vermillion, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Vermillion, Inc. – OraSure Technologies, Inc., Quest Diagnostics Incorporated, Akers Biosciences, Inc., Chembio Diagnostics, Inc., Foundation Medicine, Inc., Biocept, Inc., Myriad Genetics, Inc. and Quidel Corporation (OSUR-US, DGX-US, AKER-US, ... Read more (Read more...)

  • PR Newswire19 days ago

    Vermillion and ASPiRA Labs Kick Off Ovarian Cancer Awareness Month with 100,000th Patient Test Milestone and Ringing the Nasdaq Opening Bell

    AUSTIN, Texas, Aug. 31, 2017 /PRNewswire/ -- Vermillion, Inc. (VRML) will launch Ovarian Cancer Awareness Month by ringing the opening bell on Friday, September 1, joined by the New York City chapter of the National Ovarian Cancer Coalition. In the U.S. this year, there is estimated to be approximately 22,000 cases of ovarian cancer and more than 14,000 deaths resulting from this disease. In addition to bringing public awareness to the symptoms, plight, and aiding clinicians in the risk assessment of ovarian cancer, Vermillion has recently achieved a significant milestone as more than 100,000 women have had their ovarian cancer risk assessed with OVA1.